AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DFV Deutsche Familienversicherung AG

Investor Presentation Jan 21, 2021

116_ip_2021-01-21_0fa5d88f-d3ca-4143-a735-2e4d3e019f1d.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Preliminary figures 2020 and forecast 2021

DFV Deutsche Familienversicherung AG FRANKFURT/MAIN | 21 January 2021

FREP (DPR)

German Financial Reporting Enforcement Panel (FREP)

  • FREP has been commissioned by BaFin to conduct a sample audit of DFV's 2018 balance sheet.
  • In addition to minor comments, a disagreement arose regarding the allocation of IPO costs.
  • To avoid a protracted legal dispute, DFV agreed to FREP's findings.

IPO costs 2018 German Financial Reporting Enforcement Panel (FREP)

  • According to IFRS, the costs of the IPO, which at DFV amounted to approximately € 3.6 million for the 2018 IPO, are to be allocated according to a reasonable formula if old and new shares are placed at the same time (IAS 32.38). The amount relating to the raising of new capital, i.e. the placement of new shares, is to be reported directly in equity, while the amount for making old shares tradable is to be reported as an expense.
  • DFV conducted the IPO exclusively to acquire new capital. Old shares were not sold as part of the IPO, so the entire costs of the IPO were recognised directly in equity.
  • FREP now explicitly denies this opinion for € 0.8 million (mainly employee shares), as there is no direct connection to the capital increase.
  • For the remaining €2.8 million, it is noted that these were not allocated according to "meaningful codes" and that at least part of these costs should have been reported in the 2018 expenses. However, the FREP was unable to quantify this amount exactly. A breakdown by number of shares was not justifiable for us, as this would not have led to a causation-based breakdown.
  • We would like to make it clear that these costs are already included in DFV's equity capital, so there is no change in DFV's asset situation or future results.

CareFlex Chemie

CareFlex Chemie

Background to the decision

In BaFin's view, extrapolation from past interest rates is not permissible for strongly growing insurance companies.

Alternative methods to the common ACIR method must have the same security (90%).

The interest rate achieved by DFV in 2020 is 2.5%. DFV

CareFlex Chemie

Background to the decision

On 17 December 2020, DFV was requested by BaFin to provide evidence that the actuarial interest rate of 2% can be provided with sufficient security. A deadline of 31 December 2020 was set for this. BaFin formulated a requirement for the proof to confirm 90% security.

On 22 December 2020, DFV submitted an ALM study confirming adequate security. Since BaFin had informed the consortium at the same time that it currently did not have the proof of sufficient security of an underwriter and both R+V and Barmenia could think that it could only be DFV, we were therefore forced to exit as the consortium members – incorrectly – feared an infection of the interest rate in future premium adjustments.

Performance of the DFV AG share

Share price from 28.12.2020 to today

The termination agreement between consortium members was signed on 30 December 2020 after close of trading.

Summary

The forced exit from CareFlex is frustrating and ultimately unfounded.

Despite CareFlex Chemie, we continued our regular insurance business in 2020 without any restrictions.

What we achieved in 2020

Above-average growth despite COVID-19

Preliminary key figures FY 2020 (IFRS)

  • * Insurance industry 2020 as a total according to GDV industry data:
    • Gross premiums written: € 220.1 bn (+1.2%)
    • Policies: 448.6 million (+0.5%)

Source: https://www.gdv.de/de/themen/news/geschaeftsentwicklung-2020---zahlen-im-ueberblick-65316

Investing in our growth, profitable in our core business

Underwriting result according to IFRS

In € million FY 2019 FY 2020 YOY
change
Gross
premiums
written
90.2 114.6 +27%
Net premiums
written
54.1 62.1 +15%
Expenses
for
insurance
claims
(gross)
-44.8 -69.0 +54%
Expenses
for
insurance
claims
(net)
-29.7 -35.7 +20%
Underwriting
result
I (gross)
45.4 45.6 0%
Underwriting
result
I (net)
24.4 26.4 +8%
Costs
(without
sales
expenses;
gross)
-17.3 -22.9 +32%
Costs
(without
sales
expenses;
net)
-10.2 -12.4 +21%
Underwriting
result
II (gross)
28.1 22.7 -19%
Underwriting
result
II (net)
14.2 14.1 -1%
Sales
expenses
(gross)
-37.5 -37.7 0%
Sales
expenses
(net)
-22.8 -24.8 +9%
Underwriting
result
III (gross)
-9.4 -15.0 +60%
Underwriting
result
III (net)
-8.6 -10.7 +25%
Capital investments
(after costs)
+3.4 +0.8 -77%
Underwriting
result
IV (net)
-5.2 -9.95 +91%

Further key figures FY 2020:

  • Combined Ratio (gross): + 7.0 PP
    • FY 2020: 109.6%
    • FY 2019: 102.6%
  • Claims ratio (net): + 2.6 PP
    • FY 2020: 63.1%
    • FY 2019: 60.5%
  • Market value capital investments: + 14.3%
    • FY 2020: € 140m
    • FY 2019: € 122.5m

Note: The result may still change between +/- € 0.5 million.

The target value for the 2020 result was between € -9 and -11 million and has been achieved.

What we achieved in 2020

  • Continuation of our classic insurance business, despite:
    • CareFlex Chemie
    • COVID-19 pandemic
    • Two lockdowns
  • Achievement of our targets with stable sales costs of 12 monthly premiums:
    • 90,000 new policies

13

  • ~ € 30 million new business
  • Thanks to excellent technology and our employees, who are also committed to driving the business forward in their home offices.

Where we want to go

Our main targets for 2021:

    • 100,000 new policies
    • € 30 million new business
  • Existing premiums of € 190 million
  • Reduction of losses to € 4 million
  • New markets
  • New structures
  • New insurance products
  • More digitalisation
  • New CFO

Our growth map 2021

Solid and guaranteed growth in our core business

  • New P&C products
  • New combined insurance products

New products New risk carriers New markets

P&C

Life

In coordination with BaFin, the application will be submitted in the first half of 2021

Market entry in Austria in the second quarter 2021

More digitalisation

One focus for further growth will be more digitalisation:

  • More voice assistants
  • More online communication
  • More automation

More digitalisation: the future's insurance take out

Alexa, I want supplementary dental insurance!

In 2018, a skill was already programmed for digital product consulting that conducts a consulting dialogue and accesses the actuarial calculation core via an API interface.

We are convinced that the insurance take out of the future will also take place via digital voice assistants. That's why you can already take out DFV household, liability, dental and supplementary long-term care insurance via Amazon's Alexa.

More digitalisation: best customer portal – best Chatbot*

Customer-centricity at its best

More digitalisation: best app – free insurance take out

Simply the best for our customers

Also rated 4.9 stars in Google Play Store!

The ratings are comments from real users. They were translated into English for this presentation.

More digitalisation

Continuation of digitalisation in claims and benefits settlement

  • Increasing dark processing rate in benefits settlement
  • Increasing automation in claims settlement
  • Expansion of artificial intelligence in claims and benefits settlement
  • Completion of IT outsourcing
  • System adjustments for expansion abroad
  • Introduction of the combined insurance product

Result 2020

Result in € million

23

New CFO: Dr Karsten Paetzmann

New structure of the finance department

As of 1 February 2021, Dr Karsten Paetzmann will take over the CFO function from CEO Dr Stefan Knoll, who has been managing it on an interim base.

Career:

  • Since 2012: Various positions at BDO
    • Since 2018: Partner and Chair of Financial Services
    • Since 2013: Head of Global Financial Advisory Corporate Finance
    • Since 2012: Head of Financial Advisory
  • Since 2015: Lecturer, Frankfurt School of Finance & Management

Guidance 2021

  • + 100,000 new policies
  • + € 30 million new business
  • New products
  • New risk carriers
  • New markets

With a loss of only € 4 million*

*Without consideration of the reinsurance contract CareFlex Chemie

Outlook: continuation of profitable growth

Looking forward to your questions!

Dr Stefan M. Knoll CEO & CFO

Your contact:

Lutz Kiesewetter Head of IR & PR +49 (0)69 / 74 30 46 396 [email protected]

Our next IR dates:

18/03 Annual
Press Conference
on the 2020 financial report
24/03 Metzler Micro
Cap Days
12/05 Q1
results 2020
19/05 Annual General Meeting
21/05 German SMID Cap
One-on-One Forum

Talk to a Data Expert

Have a question? We'll get back to you promptly.